Atom Bioscience and Pharmaceutical Co., Ltd. Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2012

Location

Suzhou Jiangsu China

Primary Industry

Biotechnology

About

Based in Zhenjiang, China, and established in 2012, Atom Bioscience and Pharmaceutical Co., Ltd. operates as a pharmaceutical company that focuses on new drug discovery and treatments. The founder as well as the CEO, Dongfang Shi, worked at Genelabs Technologies and Metabolex. The CMO, Marc Gurwith, was the Executive Vice President of PaxVax Inc. In January 2022, the company raised CNY 300 million co-led by new investors GTJA Investment Group and Xicheng Jinrui. In October 2023, it raised over CNY 600 million in series D funding led by Kaitai Capital, with participation from Fortune Capital, Golden China Fund, Qiandao Group, and NNFE Investment Fund Management (Beijing). The company provides new drugs and related treatments for metabolic diseases and cancers. Its product pipelines include ABP-6016, ABP-671, ABP-745 and ABP-431. ABP-671 achieves a reduction of serum uric acid (sUA) by inhibiting renal uric acid transport protein 1 (URAT1). The drugs developed by the company can be used to treat diabetes, gout, and tumors.

Current Investors

Ch-Gemstone Capital, Youchoose Capital, Kaitai Capital

Request a demo to show more

Primary Industry

Biotechnology

Sub Industries

Biopharmaceuticals, Oncology/Cancer Treatment, Specialty Pharmaceuticals

Website

www.atombp.com

Verticals

Manufacturing

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.